Benyuan Zhengyang Gene Technology

Beijing Benyuan Zhengyang Gene Technology is a clinical-stage biotechnology company headquartered in Beijing, China, dedicated to the development of innovative gene therapies. Established in 2004, the company focuses on utilizing adeno-associated virus (AAV) vectors to treat rare genetic disorders and neurodegenerative diseases. Its robust pipeline includes programs for Hemophilia A and B, Pompe disease, and Spinal Muscular Atrophy, with several candidates currently in clinical trials. Benyuan Zhengyang operates a comprehensive technology platform that spans from early-stage drug discovery to large-scale GMP manufacturing of viral vectors. In addition to its internal R&D, the company provides high-quality CDMO services to support the global gene therapy industry. Through its integrated capabilities, Benyuan Zhengyang aims to provide transformative treatments for patients with unmet medical needs.